×
Harmony Biosciences Holdings Share Holder Equity 2020-2024 | HRMY
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Harmony Biosciences Holdings share holder equity from 2020 to 2024. Share holder equity can be defined as the sum of preferred and common equity items
View More
Harmony Biosciences Holdings Share Holder Equity 2020-2024 | HRMY
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Harmony Biosciences Holdings share holder equity from 2020 to 2024. Share holder equity can be defined as the sum of preferred and common equity items
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$170.3B
Vertex Pharmaceuticals (VRTX)
$122B
Bristol Myers Squibb (BMY)
$112.5B
Gilead Sciences (GILD)
$111.9B
Regeneron Pharmaceuticals (REGN)
$91.4B
CSL (CSLLY)
$90.8B
GSK (GSK)
$76.6B
Argenex SE (ARGX)
$35.2B
Alnylam Pharmaceuticals (ALNY)
$34.8B
BioNTech SE (BNTX)
$25.9B
Biogen (BIIB)
$25.3B
Illumina (ILMN)
$24.5B
Moderna (MRNA)
$20.6B
BeiGene (BGNE)
$20.2B
Genmab (GMAB)
$15.1B
Incyte (INCY)
$14.6B
Exact Sciences (EXAS)
$13.1B
BioMarin Pharmaceutical (BMRN)
$12.6B
Insmed (INSM)
$12.2B
Bio-Techne Corp (TECH)
$12B
Vaxcyte (PCVX)
$11.9B
Sarepta Therapeutics (SRPT)
$11.7B
QIAGEN (QGEN)
$10B
Exelixis (EXEL)
$9.8B
Bio-Rad Laboratories (BIO.B)
$9.3B
Revolution Medicines (RVMD)
$9.3B
Intra-Cellular Therapies (ITCI)
$9.1B
Roivant Sciences (ROIV)
$8.5B
Legend Biotech (LEGN)
$8B
Repligen (RGEN)
$7.8B